Recordati's €2.3B Secret: Why MENA Pharma Is Playing the Wrong Game

They didn't chase population. They chased profit velocity .

While regional players expand into every large market, Recordati avoided LATAM and China entirely. While competitors build massive sales forces, they pivoted MENA to a low-touch distributor model.

The result?

Home market dependency: 84% → 14%

COGS: ~30% (vs. 40% GCC average)

R&D: 12.2% of revenue (vs. <5% MENA peers)

Operating income: ~30% and holding strong

But here's the uncomfortable truth: Most MENA pharma companies are still optimizing for 2010. Recordati optimized for 2026.

They didn't win by being everywhere. They won by being strategically selective .

📎 The complete strategic teardown is attached.

Inside, you'll find:

The exact M&A playbook (11 deals, €417M, zero mega-deals)

Economic benchmarks every MENA CFO should track

Why they avoid "big" markets and what that means for your expansion strategy

The question isn't whether Recordati's model works. It's whether MENA leaders will adapt before the window closes.

Full study attached below 👇